Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2011

Open Access 01-12-2011 | Case report

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Authors: Chiara Tommasi, Rita Bellagamba, Massimo Tempestilli, Antonio D'Avolio, Anna L Gallo, Jelena Ivanovic, Emanuele Nicastri, Leopoldo P Pucillo, Pasquale Narciso

Published in: Malaria Journal | Issue 1/2011

Login to get access

Abstract

The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.
Appendix
Available only for authorised users
Literature
1.
Boggild AK, Parise ME, Lewis LS, Kain KC: Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg. 2007, 76: 208-223.PubMed
2.
3.
van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, Gelinck L, Kroon F, Wit FW, Van Schaik RH, Kuks PF, Burger DM: Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS. 2010, 24: 1223-1226. 10.1097/QAD.0b013e3283389129.CrossRefPubMed
4.
Schöller-Gyüre M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM: Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009, 48: 561-574. 10.2165/10895940-000000000-00000.CrossRefPubMed
5.
Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998, 37: 3594-3601. 10.1021/bi972709x.CrossRefPubMed
6.
Srinivas R, Middlemas D, Flynn P, Fridland A: Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother. 1998, 42: 3157-3162.PubMedCentralPubMed
7.
Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA: Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharm Ther. 2008, 83: 293-299. 10.1038/sj.clpt.6100281.CrossRef
8.
Abel S, Back DJ, Vourvahis M: Maraviroc: pharmacokinetics and drug interactions. Antivir Ther. 2009, 14: 607-618.CrossRefPubMed
9.
Meanwell NA, Kadow JF: Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs. 2007, 8: 669-681.PubMed
10.
Tommasi C, Tempestilli M, Fezza R, Bellagamba R, Nicastri E, D'offizi G, Pucillo LP, Narciso P: A rare case of severe myopathy associated with etravirine use. AIDS. 2010, 24: 1088-1090. 10.1097/QAD.0b013e3283382f65.CrossRefPubMed
11.
D'Avolio A, Baietto L, Siccardi M, Sciandra M, Simiele M, Oddone V, Bonora S, Di Perri G: An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other anti-retroviral agents in the plasma of HIV-infected patients. Ther Drug Monit. 2008, 30: 662-669. 10.1097/FTD.0b013e318189596d.CrossRefPubMed
12.
D'Avolio A, Simiele M, Baietto L, Siccardi M, Sciandra M, Patanella S, Bonora S, Di Perri G: A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther Drug Monit. 2010, 32: 86-92. 10.1097/FTD.0b013e3181cacbd0.CrossRefPubMed
Metadata
Title
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
Authors
Chiara Tommasi
Rita Bellagamba
Massimo Tempestilli
Antonio D'Avolio
Anna L Gallo
Jelena Ivanovic
Emanuele Nicastri
Leopoldo P Pucillo
Pasquale Narciso
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2011
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-10-141

Other articles of this Issue 1/2011

Malaria Journal 1/2011 Go to the issue

Research

Accuracy of malaria rapid diagnostic tests in community studies and their impact on treatment of malaria in an area with declining malaria burden in north-eastern Tanzania

Methodology

Modelling malaria elimination on the internet

Methodology

Specific, sensitive and rapid detection of human plasmodium knowlesi infection by loop-mediated isothermal amplification (LAMP) in blood samples

Research

Evaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites

Research

Influence of climate and river level on the incidence of malaria in Cacao, French Guiana

Research

Validation of oral fluid samples to monitor serological changes to Plasmodium falciparum: An observational study in southern Zambia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits